Study title: Caffeine as a Therapeutic Agent in Parkinson’s disease
Principal investigators: Dre. Daniela Berg, Dr. Ron Postuma
Site Address: MUHC-Montreal General Hospital, 1650 Cedar Avenue Montreal, Quebec, H3G 1A4
Background: Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by progressive motor disability and many disabling non-motor symptoms. Recently epidemiologic studies have linked lifelong use of caffeine, to a lower risk of PD.
Purpose of the study: The purpose of the study is to assess acute symptomatic benefits of caffeine on motor manifestations of diseaseand-term potential benefits of caffeine upon overall PD severity, severity of motor manifestations, motor complications, non-motor manifestations, medication utilization, and health care costs.